share_log

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67

Wedbush 对阿佩利斯制药保持中立,将目标价上调至67美元
Benzinga Real-time News ·  2022/09/12 09:48

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $55 to $67.

Wedbush分析师劳拉·奇科维持Apellis Pharmicals(纳斯达克股票代码:APLS)为中性,并将目标股价从55美元上调至67美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发